Education
About Us
Working with TipRanks
Follow Us
Dr. Lal PathLabs Limited (IN:LALPATHLAB)
:LALPATHLAB
LALPATHLAB Stock Chart & Stats
₹1472.95
-₹106.10(-3.42%)
At close: 4:00 PM EST
₹1472.95
-₹106.10(-3.42%)
Day’s Range― - ―
52-Week Range₹1,147.55 - ₹1,771.30
Previous CloseN/A
Volume152.98K
Average Volume (3M)3.61K
Market Cap
₹235.93B
Enterprise Value₹229.67B
Total Cash (Recent Filing)₹11.64B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)44.0
Beta0.69
Next Earnings
May 14, 2026EPS Estimate
7.4Next Dividend Ex-DateN/A
Dividend Yield0.89%
Share Statistics
EPS (TTM)6.70
Shares Outstanding167,555,020
10 Day Avg. Volume2,182
30 Day Avg. Volume3,614
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)9.21
Price to Sales (P/S)8.13
P/FCF Ratio38.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,577.00Price Target Upside7.06% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Margins And Profit ConversionSustained gross and net margins near 60.8% and 19.8% indicate durable pricing power and operational efficiency. Over a 2–6 month horizon this margin profile supports reinvestment in labs and service centers, funds discretionary spend, and cushions against cost inflation while preserving long-term profitability.
Strong Cash GenerationConsistent operating cash flow and growing free cash flow signal the company can fund organic expansion and maintenance capex without heavy external financing. This cash convertibility supports network scaling, working capital needs, and shareholder returns, enhancing financial flexibility over months to years.
Conservative Balance SheetA low debt-to-equity profile and strong equity base reduce financial risk and preserve optionality. This conservative capital structure enables investment in diagnostic infrastructure, opportunistic M&A, or weathering demand shocks without eroding liquidity or forcing asset sales over the medium term.
Bears Say
Suboptimal Return On EquityROE that 'shows room for improvement' suggests the company is not extracting maximum value from shareholder capital. Unless management enhances asset utilization or raises incremental returns through higher-margin services, shareholder returns may trail peers over a sustained 2–6 month period.
Moderate Revenue Growth RateRevenue growth around 10.8% is positive but modest for a healthcare diagnostics player in a growing market. Slower top-line expansion can limit economies of scale, slow margin expansion, and reduce the pace at which the company gains share or justifies capacity additions over the medium term.
Volume And Test-mix SensitivityBusiness model dependence on volumes, mix and service levels creates structural sensitivity to patient footfall, hospital contracts, and competitive pricing. Adverse shifts in mix or reduced volumes can compress margins and utilization, requiring sustained operational focus to protect profitability.
Dr. Lal PathLabs Limited News
LALPATHLAB FAQ
What was Dr. Lal PathLabs Limited’s price range in the past 12 months?
Dr. Lal PathLabs Limited lowest stock price was ₹1147.55 and its highest was ₹1771.30 in the past 12 months.
What is Dr. Lal PathLabs Limited’s market cap?
Dr. Lal PathLabs Limited’s market cap is ₹235.93B.
When is Dr. Lal PathLabs Limited’s upcoming earnings report date?
Dr. Lal PathLabs Limited’s upcoming earnings report date is May 14, 2026 which is in 78 days.
How were Dr. Lal PathLabs Limited’s earnings last quarter?
Dr. Lal PathLabs Limited released its earnings results on Jan 30, 2026. The company reported ₹6.7 earnings per share for the quarter, missing the consensus estimate of ₹7.625 by -₹0.925.
Is Dr. Lal PathLabs Limited overvalued?
According to Wall Street analysts Dr. Lal PathLabs Limited’s price is currently Undervalued.
Does Dr. Lal PathLabs Limited pay dividends?
Dr. Lal PathLabs Limited pays a Quarterly dividend of ₹7 which represents an annual dividend yield of 0.89%. See more information on Dr. Lal PathLabs Limited dividends here
What is Dr. Lal PathLabs Limited’s EPS estimate?
Dr. Lal PathLabs Limited’s EPS estimate is 7.4.
How many shares outstanding does Dr. Lal PathLabs Limited have?
Dr. Lal PathLabs Limited has 167,555,020 shares outstanding.
What happened to Dr. Lal PathLabs Limited’s price movement after its last earnings report?
Dr. Lal PathLabs Limited reported an EPS of ₹6.7 in its last earnings report, missing expectations of ₹7.625. Following the earnings report the stock price went up 0.946%.
Which hedge fund is a major shareholder of Dr. Lal PathLabs Limited?
Currently, no hedge funds are holding shares in IN:LALPATHLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company also offers lab staff training; technical; and lab management services. As of March 31, 2022, the company had 277 clinical laboratories, including National Reference Lab at Delhi and Regional Reference Lab at Kolkata; and 4,731 patient service centers and 10,599 pick-up points. Dr. Lal PathLabs Limited was founded in 1949 and is based in Gurugram, India.
LALPATHLAB Stock 12 Month Forecast
Average Price Target
₹1,577.00
▲(7.06% Upside)
Technical Analysis
Jupiter Life Line Hospitals Ltd.
―
Krsnaa Diagnostics Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―